Viruses are the masters of hostile takeovers. They have evolved to infect, replicate, and spread as rapidly and mercilessly as possible by hijacking the cellular processes of their host to their own advantage. Their infections often have devastating effects on not only the host but also, in many cases, the entire host population, making viral infections one of the largest threats to global health. Although we do have powerful weapons against viruses in the form of vaccines and public policies that encourage vaccination, vaccines for a number of viral pathogens remain unavailable. This requires the development of antiviral therapeutics, such as the combination therapy with small molecules, which have provided a cure for hepatitis C virus (HCV) infection and enabled long-term control of human immunodeficiency virus (HIV) infection. While these successes demonstrate the profound impact that antiviral therapeutics can have on human health, antiviral resistance threatens to limit the efficacy of these therapies, and the development of analogous agents to treat the host of other viruses causing human disease remains challenging. Additionally, due to highly diverse mechanisms of viral infection and replication, there are no broadly active antivirals akin to the broad-spectrum antibiotics available to combat bacterial pathogens. Each viral pathogen requires a dedicated investment of resources and time. Unfortunately, time is not on our side when dealing with the emergence of new viral pathogens that, thanks to globalization, can spread with astonishing speed, as most dramatically evidenced by the current global pandemic caused by the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). Driven by a clear unmet need for effective therapeutics against viral pathogens, the field has been pushing hard against these microscopic, yet formidable, opponents to enhance established antiviral strategies as well as develop innovative approaches for new classes of antiviral targets, including host factors, and new antiviral modalities, such as agents that act by novel mechanisms and that may have broad-spectrum activity and high natural barriers to resistance. Drug repurposing, structural genomics, computational screening and design, and sophisticated target-based and phenotypic screening platforms are being leveraged to expedite antivirals discovery. Advances in B cell cloning and recombinant antibody technologies are being applied to rapidly identify therapeutic antibodies. Virologists, medicinal chemists, chemical biologists, structural biologists, computational scientists, and clinicians are forming interdisciplinary collaborative teams to better understand nuances of viral infections and disease progression, with the aim of stratifying patient populations and developing treatment options for different stages of the disease. In recognition of the unprecedented times we are all living through, the importance of many exciting developments in this area of infectious diseases research, and the need to advocate for broad support, ACS Infectious Diseases will publish a Special Issue on Antiviral Therapeutics. We invite submission of Articles, Letters, Reviews, Viewpoints, and Perspectives from academic groups, not-for-profits, and industry on research in this area. This includes work on agents that inhibit viral replication or pathogenesis or that modulate the host response to viral pathogens; platforms for antivirals discovery and optimization; experimental models for the evaluation of antviral agents; assays and technologies for diagnosis of viral infection and quantification of the host response to viral infection. We strongly encourage the submission of research on the discovery, mechanistic characterization, and validation of both small molecule and biological agents applied to both established and newly emerging viral pathogens. By submitting your work to this Special Issue, you will take advantage of this extraordinary opportunity to add your voice and your science to an area that recent events have brought to the forefront of interests of not only the scientific community but also policy makers, funders, and the public. Through this Special Issue, we hope to highlight what we, a community of researchers interested in antiviral therapeutic discovery, can achieve, and we invite you to join us. The deadline for manuscript submission is December 15, 2020. Submit manuscripts via https://acsparagonplus.acs.org and select the topic “Antiviral Therapeutics” in the drop-down menu to request consideration for this Special Issue. Presubmission inquiries are recommended to ensure the appropriateness of your manuscript for this Special Issue and can be sent to [email protected]. Please consult the Author Guidelines (http://pubs.acs.org/paragonplus/submission/aidcbc/aidcbc_authguide.pdf) for more information about the journal, manuscript types, and instructions for manuscript preparation. Views expressed in this editorial are those of the author and not necessarily the views of the ACS. This article has not yet been cited by other publications.

中文翻译：

---

征文通知：抗病毒治疗。

病毒是敌对收购的主人。它们通过劫持其宿主的细胞过程使其自身利益而尽可能快地，无情地感染，复制和传播。它们的感染通常不仅对宿主造成毁灭性影响，而且在许多情况下，还对整个宿主种群造成破坏性影响，使病毒感染成为对全球健康的最大威胁之一。尽管我们确实拥有以疫苗和鼓励接种疫苗的公共政策等形式抵抗病毒的强大武器，但仍无法获得用于多种病毒病原体的疫苗。这就需要开发抗病毒疗法，例如与小分子的联合疗法，这些疗法为丙型肝炎病毒（HCV）感染提供了治疗方法，并能够长期控制人类免疫缺陷病毒（HIV）感染。尽管这些成功证明了抗病毒疗法可能对人类健康产生深远影响，但抗病毒耐药性威胁着限制这些疗法的功效，并且开发类似药物以治疗导致人类疾病的其他病毒宿主仍然具有挑战性。此外，由于病毒感染和复制的机制多种多样，因此没有像抗击细菌病原体的广谱抗生素一样具有广泛活性的抗病毒药。每种病毒病原体都需要投入专门的资源和时间。不幸的是，在应对新病毒病原体的出现时，我们没有时间了，由于全球化，这种病原体可以以惊人的速度传播，严重急性呼吸系统综合症冠状病毒2（SARS-CoV-2）引起的当前全球大流行最明显地证明了这一点。在对病毒病原体的有效治疗方法的明确未满足需求的推动下，该领域一直在努力对抗这些微观但强大的对手，以增强既定的抗病毒策略以及开发针对新型抗病毒靶标（包括宿主因子）的创新方法，以及新的抗病毒方式，例如以新颖机制起作用的药物，可能具有广谱活性和对耐药性的高天然屏障。重新利用药物，结构基因组学，计算筛选和设计以及基于靶标和表型的复杂筛选平台可加快抗病毒药物的发现。B细胞克隆和重组抗体技术的进步已被用于快速鉴定治疗性抗体。病毒学家，药物化学家，化学生物学家，结构生物学家，计算科学家和临床医生正在组成跨学科的合作团队，以更好地了解病毒感染和疾病进展的细微差别，目的是对患者人群进行分层并针对疾病的不同阶段开发治疗方案。认识到我们所有人都生活在前所未有的时代，在传染病研究领域中许多令人振奋的发展的重要性以及需要倡导广泛支持的认识，计算科学家和临床医生正在组建跨学科协作团队，以更好地了解病毒感染和疾病进展的细微差别，目的是对患者人群进行分层并针对疾病的不同阶段制定治疗方案。认识到我们所有人都生活在前所未有的时代，在传染病研究领域中许多令人振奋的发展的重要性以及需要倡导广泛支持的认识，计算科学家和临床医生正在组建跨学科协作团队，以更好地了解病毒感染和疾病进展的细微差别，目的是对患者人群进行分层并针对疾病的不同阶段制定治疗方案。认识到我们所有人都生活在前所未有的时代，在传染病研究领域中许多令人振奋的发展的重要性以及需要倡导广泛支持的认识，ACS传染病将出版有关抗病毒治疗的特刊。我们邀请学术团体，非营利组织和行业界就此领域的研究提交文章，信函，评论，观点和观点。这包括研究抑制病毒复制或发病机制或调节宿主对病毒病原体反应的药物；发现和优化抗病毒药物的平台；评估抗病毒药物的实验模型；诊断病毒感染的方法和技术以及宿主对病毒感染的反应的量化。我们强烈鼓励提交有关既适用于既定病毒病原体也包括新兴病毒病原体的小分子和生物制剂的发现，机理表征和验证的研究报告。通过将您的作品提交本期特刊，您将利用这一难得的机会，在最近发生的事件使科学界，政策制定者，资助者和公众的利益引起关注的领域中增加自己的声音和科学知识。通过本期特刊，我们希望着重强调我们（一个对抗病毒治疗发现感兴趣的研究人员社区）可以实现的目标，并邀请您加入我们。提交论文的截止日期是2020年12月15日。通过https://acsparagonplus.acs.org提交论文，并在下拉菜单中选择主题“抗病毒治疗”，以请求考虑本期特刊。建议您进行提交前查询，以确保您的稿件适合本特刊，并可以发送至[电子邮件保护]。请参阅作者指南（http://pubs.acs.org/paragonplus/submission/aidcbc/aidcbc_authguide.pdf），以获取有关期刊，手稿类型以及手稿准备说明的更多信息。本社论中表达的观点只是作者的观点，不一定是ACS的观点。本文尚未被其他出版物引用。